Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Hee Jung | - |
dc.contributor.author | Lee, Soohyeon | - |
dc.date.accessioned | 2021-12-08T23:41:49Z | - |
dc.date.available | 2021-12-08T23:41:49Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/130437 | - |
dc.description.abstract | Purpose: The standard schedule for sunitinib treatment is 4 weeks on and 2 weeks off (4/2) in first-line treatment for metastatic renal cell carcinoma (mRCC). Schedule modifications, inducting 2 weeks on and 1 week off (2/1), appear to reduce the total number of treatment-related adverse events (TRAEs) without compromising efficacy. Even though TRAEs can qualitatively differ from each other, it is not dear as to what effects a 2/1 schedule has on individual TRAEs. Materials and Methods: This meta-analysis included one randomized controlled trial (RCT) and four non-randomized controlled studies (non-RCTs) that compared the two schedules in parallel. The primary objective was to estimate risk of individual adverse events (AEs) with a sunitinib 2/1 schedule versus a 4/2 schedule. Seven representative AEs were evaluated as standard data for the RCT and as weighted pooling data of the non-RCI's. Random effects modelling with Review Manager v5.3 was used to pool study-level data using the inverse-variance of each study as the weight. Results: The five selected studies included a total of 484 patients with mRCC. Risk ratios for fatigue for a 2/1 schedule were significantly lower than those for a 4/2 schedule {0.69[95% confidence intervals (CI), 0.51, 0.95] in the RCT and 0.77 (95% CI, 0.63, 0.94) in the non-RCTs}. Other TRAEs, except diarrhea and anorexia, also tended to decrease in both sets. Efficacy outcomes were comparable between 2/1 and standard schedules. Conclusion: This meta-analysis suggests that a 2/1 schedule of sunitinib lowers the risk of fatigue and the occurrence other AEs without compromising efficacy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | YONSEI UNIV COLL MEDICINE | - |
dc.subject | RENAL-CELL CARCINOMA | - |
dc.subject | EFFICACY | - |
dc.subject | SU11248 | - |
dc.subject | INHIBITOR | - |
dc.subject | TOXICITY | - |
dc.subject | OUTCOMES | - |
dc.subject | THERAPY | - |
dc.subject | TRIAL | - |
dc.title | Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Soohyeon | - |
dc.identifier.doi | 10.3349/ymj.2020.61.10.837 | - |
dc.identifier.scopusid | 2-s2.0-85091617891 | - |
dc.identifier.wosid | 000576629500001 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, v.61, no.10, pp.837 - 843 | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.citation.title | YONSEI MEDICAL JOURNAL | - |
dc.citation.volume | 61 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 837 | - |
dc.citation.endPage | 843 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002626526 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | RENAL-CELL CARCINOMA | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SU11248 | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Sunitinib | - |
dc.subject.keywordAuthor | drug administration schedule | - |
dc.subject.keywordAuthor | meta-analysis | - |
dc.subject.keywordAuthor | renal cell carcinoma | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.